Related Experiment Video
Updated: Nov 15, 2025
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Failure of adjuvant treatment for malignant melanoma - what next?
Background:
The possibilities of adjuvant therapy of malignant melanoma have significantly expanded in recent years. Based on the results of clinical studies, immunotherapy represented by checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab) and targeted therapies (dabrafenib plus trametinib) in patients with a proven mutation in the BRAF gene were included in the treatment protocols. In the Czech Republic, nivolumab and combination therapy of dabrafenib with trametinib are currently available for clinical practice. However, the question remains how to proceed if relapse or generalization occurs after the adjuvant treatment. The following case study describes one of possible solutions.
Case Report:
The article presents the failure of adjuvant nivolumab immunotherapy in a patient with locally advanced stage IIIC malignant melanoma. Ipilimumab has been selected as a treatment choice and demonstrated its efficacy. However, its administration was associated with immune-related side effects. These were dia-gnosed and successfully treated in the internal department in close cooperation with our department of oncology.
Conclusion:
Although adjuvant therapy has significantly reduced a risk of disease relapse, there is a cohort of patients in whom adjuvant therapy fails. Failure may occur after the end of the therapy or, as in our case, during the therapy. Based on currently available data, it is not possible to unambiguously choose the optimal procedure after adjuvant therapy failure. Currently, there is no other way than following clinical experience and reimbursement regulations, or enrolling the patient in a clinical trial. Immune-related adverse effects require particular attention as they are unique due to their mechanism of origin and often require a multidisciplinary approach.
Insights
Adjuvant immunotherapy for malignant melanoma can fail, necessitating alternative treatments like ipilimumab. Careful management of immune-related side effects is crucial for successful outcomes in melanoma relapse.
Area of Science:
- Oncology
- Immunotherapy
- Melanoma Research
Background:
- Adjuvant therapy options for malignant melanoma have expanded, including checkpoint inhibitors (nivolumab, ipilimumab) and targeted BRAF gene therapies.
- Nivolumab and dabrafenib plus trametinib are available in the Czech Republic for adjuvant treatment.
- Challenges remain in managing melanoma relapse or progression after adjuvant therapy.
Observation:
- This case study details the failure of adjuvant nivolumab immunotherapy in a patient with stage IIIC malignant melanoma.
- Ipilimumab was chosen as an alternative treatment and proved effective.
- Immune-related side effects occurred during ipilimumab administration but were successfully managed.
Findings:
- Adjuvant therapy can fail during or after treatment, with no definitive optimal procedure established.
- Clinical experience, reimbursement regulations, and clinical trials guide treatment decisions post-adjuvant therapy failure.
- Immune-related adverse effects from immunotherapy require specialized, multidisciplinary care.
Implications:
- This case highlights ipilimumab as a viable option following nivolumab failure in advanced melanoma.
- Effective management of immune-related side effects is critical for treatment success.
- Further research is needed to establish clear guidelines for managing adjuvant therapy failure in melanoma.
Related Concept Videos
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy